RxDoctor Payments Data

Meredith Wasserman, MD

Urology · Providence, RINPI 1518496264

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,492 of the $2,179 with a category attached, or 68.5%. Medtronic accounts for 76.2% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $928, 4.8 times the $194 reported in 2022. That places this record below the midpoint for urology clinicians in RI, where the typical reported total is $2,349.

$2,179in general payments, 2019–2025

Across 30 payments — averaging $72.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$404
  • Sumitomo Pharma America, Inc.$39
  • Astellas Pharma US Inc$27
  • Urogen Pharma, Inc.$24
  • Novo Nordisk$24

What the payments were for

  • Travel & lodging$68732%
  • Food & beverage$1,49268%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,179 in reported general payments places this provider in the 45th percentile of 55 urology providers in Rhode Island.

See all urology providers in Rhode Island

Medicare billing

Part B allowed, 2024
$27,452
Medicare patients
90
Services billed
492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron144$112,040
MyrbetriqMirabegron151$94,108
PremarinEstrogens, Conjugated12$5,325
Estradiol76$4,819
YuvafemEstradiol15$1,903
Methenamine Hippurate24$1,879
Solifenacin Succinate21$1,077
Trospium Chloride17$798
Tamsulosin Hcl41$526
NitrofurantoinNitrofurantoin Macrocrystal16$425
Oxybutynin Chloride ErOxybutynin Chloride20$416
Sodium ChlorideSodium Chloride Irrig Solution17$355
Alfuzosin Hcl ErAlfuzosin Hcl12$351
Finasteride16$242
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst24$215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$39$112,040144 claims
Astellas Pharma US IncMyrbetriq$27$94,108151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 55 urology providers in Rhode Island.

Other urology in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →